ACUTE RETINAL NECROSIS AFTER ADMINISTRATION OF ADALIMUMAB, A SYSTEMIC ANTITUMOR NECROSIS FACTOR ANTIBODY.
Citation: RETINAL Cases & Brief Reports. 12(4):307-309, 2018 Fall.PMID: 27997458Institution: MedStar Union Memorial HospitalDepartment: MedicineForm of publication: Journal ArticleMedline article type(s): Case Reports | Journal ArticleSubject headings: *Adalimumab/ae [Adverse Effects] | *Anti-Inflammatory Agents/ae [Adverse Effects] | *Retinal Necrosis Syndrome, Acute/ci [Chemically Induced] | Humans | Male | Middle Aged | Tumor Necrosis Factor-alpha/ai [Antagonists & Inhibitors]Year: 2018Local holdings: Available online through MWHC library: 2007 - presentISSN:- 1935-1089
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 27997458 | Available | 27997458 |
Available online through MWHC library: 2007 - present
CONCLUSION: Physicians prescribing tumor necrosis factor alpha antagonist immunosuppressive therapy should be aware of the potential of developing acute retinal necrosis.
METHODS: Case report.
PURPOSE: To report a case of acute retinal necrosis in a patient on anti-tumor necrosis factor alpha immunosuppressive therapy.
RESULTS: A 47-year-old man with psoriasis presented with blurred vision and floaters in the left eye 4 days after receiving his fourth dose of adalimumab, a tumor necrosis factor alpha antagonist. He was diagnosed with acute retinal necrosis and was treated with intravenous acyclovir as well as prophylactic laser barricade. Seven years later, he is 20/20 with no history of a retinal detachment.
English